Depression is “vastly underdiagnosed” in people with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), states a literature review published online in the Harvard Review of Psychiatry.
The protein GPR56 may provide an easy-to-measure biomarker of a patient’s response to antidepressants as well as a novel drug target for the treatment of major depressive disorder, according to a published study.
Women who had depressive symptoms during their third trimester of pregnancy, or persistently before and after giving birth, were twice as likely to have babies with very low levels of immunoglobulin A.
AXS-05, an investigational modulated-delivery tablet combining dextromethorphan and bupropion, significantly improved symptoms of depression in patients with major depressive disorder (MDD) in a recent phase 3 trial, announced developer Axsome Therapeutics Inc.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.